These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22212721)

  • 21. Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing sulfonamido as potential PI3Kα inhibitors.
    Yin Y; Hu JQ; Wu X; Sha S; Wang SF; Qiao F; Song ZC; Zhu HL
    Bioorg Med Chem; 2019 Jun; 27(11):2261-2267. PubMed ID: 31029551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, Biological Evaluation, and Molecular Modeling of 2-Difluoromethylbenzimidazole Derivatives as Potential PI3Kα Inhibitors.
    Wang X; Zhang M; Zhu R; Wu Z; Wu F; Wang Z; Yu Y
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
    Liao W; Wang Z; Han Y; Qi Y; Liu J; Xie J; Tian Y; Lei Q; Chen R; Sun M; Tang L; Gong G; Zhao Y
    Eur J Med Chem; 2020 Jul; 197():112309. PubMed ID: 32375077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
    Ma CC; Liu ZP
    Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological explorations of eco-friendly amide substituted (Z)-β-enaminones as anti-breast cancer drugs.
    Subramamiam P; Ramasubbu C; Athiramu S; Arumugam S; Alagumuthu M
    Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800244. PubMed ID: 30515835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kα inhibitors that inhibit metastasis.
    Schmidt-Kittler O; Zhu J; Yang J; Liu G; Hendricks W; Lengauer C; Gabelli SB; Kinzler KW; Vogelstein B; Huso DL; Zhou S
    Oncotarget; 2010 Sep; 1(5):339-48. PubMed ID: 21179398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3Kα.
    Yin Y; Zhou Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
    Bioorg Chem; 2019 Nov; 92():103238. PubMed ID: 31499259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors.
    Wu P; Su Y; Liu X; Yang B; He Q; Hu Y
    Bioorg Med Chem; 2012 May; 20(9):2837-44. PubMed ID: 22480851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
    Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
    J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3Kα.
    Yin Y; Zhang YQ; Jin B; Sha S; Wu X; Sangani CB; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
    Bioorg Med Chem; 2015 Mar; 23(6):1231-40. PubMed ID: 25693787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.
    Türe A; Kahraman DC; Cetin-Atalay R; Helvacıoğlu S; Charehsaz M; Küçükgüzel İ
    Comput Biol Chem; 2019 Feb; 78():227-241. PubMed ID: 30579980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
    Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
    Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
    Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
    Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
    [No Abstract]   [Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
    Desai S; Desai V; Shingade S
    Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
    O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
    ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.